An artificial intelligence-based model for prediction of clonal hematopoiesis variants in cell-free DNA samples.

Journal: NPJ precision oncology
Published Date:

Abstract

Circulating tumor DNA is a critical biomarker in cancer diagnostics, but its accurate interpretation requires careful consideration of clonal hematopoiesis (CH), which can contribute to variants in cell-free DNA and potentially obscure true tumor-derived signals. Accurate detection of somatic variants of CH origin in plasma samples remains challenging in the absence of matched white blood cells sequencing. Here we present an open-source machine learning framework (MetaCH) which classifies variants in cfDNA from plasma-only samples as CH or tumor origin, surpassing state-of-the-art classification rates.

Authors

  • Gustavo Arango-Argoty
    Oncology Data Science, Oncology R&D, AstraZeneca, Waltham, MA, USA. gustavo.arango@astrazeneca.com.
  • Marzieh Haghighi
    Oncology R&D, AstraZeneca, Waltham, MA, USA.
  • Gerald J Sun
    Oncology Data Science, Oncology R&D, AstraZeneca, Waltham, MA, USA.
  • Elizabeth Y Choe
    Oncology Data Science, Oncology R&D, AstraZeneca, Waltham, MA, USA.
  • Aleksandra Markovets
    Oncology R&D, AstraZeneca, Waltham, MA, USA.
  • J Carl Barrett
    Oncology R&D, AstraZeneca, Waltham, MA, USA.
  • Zhongwu Lai
    Oncology R&D, AstraZeneca, Waltham, MA, USA.
  • Etai Jacob
    Oncology Data Science, Oncology R&D, AstraZeneca, Waltham, MA, USA.

Keywords

No keywords available for this article.